Abstract

Thirteen abietane-type diterpenoids, including seven previously undescribed compounds and six known analogs, were isolated from the root and aerial parts of Phlegmariurus carinatus. Their structures were elucidated by comprehensive spectroscopic data analysis (UV, IR, NMR, and HRESIMS) and quantum chemical calculations (ECD and calculated 13C NMR analysis). Notably, these compounds exhibited high structural diversity. Compounds 1-8 possessed six distinct fused ring systems. Phlecarinatones I (2) and J (3) were identified as rare 6,7-seco-abietane diterpenoids featuring a five-membered lactone ring B. Compounds (1-12) were evaluated for their anti-proliferative activities in the U-251 cell line. In particular, phlecarinatone I (2) exhibited potential inhibitory effects on U251 cell proliferation, with an IC50 value of 13.88 ± 1.82 μM. To elucidate the underlying molecular mechanism, p53 signal pathway was enriched from our RNA-seq data. Further investigations using Western blot and immunofluorescence assays confirmed that p53 expression was up-regulated in a concentration-independent manner. Additionally, molecular docking studies suggested 2 likely binds to the MDM2-p53 binding region. Finally, an shRNA-mediated MDM2 knockdown experiment provided definitive evidence that 2 acts as a potent inhibitor of glioma proliferation, operating via the modulation of the MDM2-p53 pathway. These findings suggest that 2 might be a valuable of lead compound with anti-proliferative activity.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.